Based in Pleucadeuc (Morbihan – France), BCF Life Sciences is a leader in the extraction of amino acids. The company generated revenue of roughly €30m in 2017, more than 60% from exports.

BCF Life Sciences designs, produces and sells three product ranges:

• L-Cystine and L-Tyrosine, amino acids primarily used in child nutrition, food supplements and health nutrition;

• Carbocisteine, active pharmaceutical ingredient;

• Free amino acid mix for use in animal nutrition (especially veterinary dietary products for dogs and cats, aquaculture) and foliar biostimulants.

Since Céréa Capital and Sodero Gestion acquired BCF Life Sciences, alongside the company’s senior management, in August 2012, the group’s economic performance has substantially increased, notably thanks to the commercial success of free amino acid powders. To support its growth, the group invested €8m in a drying tower in 2015.

MBO & Co’s acquisition of BCF Life Sciences will give the group’s management, which reinvests to strengthen its majority, the financial resources and human support needed to continue the group’s development.

Jacques Pidoux and Renaud Sergheraert, CEOs at BCF Life Sciences, said: “The arrival of MBO & Co opens a new page to further accelerate the strategy of innovation and international development, whilst ensuring the ongoing pursuit of industrial investments essential to the Group’s growth.”

Xavier de Prévoisin, Partner at MBO & Co, added: “BCF Life Sciences is a highly innovative company with a strong international base. By investing in its R&D, commercial and production resources, we will accelerate its growth and reposition the group on products with a higher added value. We are delighted to accompany BCF Life Sciences and its management in this new phase.”